FindTrial
Sign In

Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502691-23-00
Acronym
IMIB-BICOV-2022-01
Enrollment
20
Registered
2023-06-21
Start date
2023-02-27
Completion date
Unknown
Last updated
2023-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Brief summary

The safety variable of the study will be postoperative Morbidity and Mortality. Morbidity will be defined based on the NCI‐CTCAE v4 scale classification., The variables related to the treatment effectiveness will be disease free and overall survival.

Detailed description

The secondary variable will be the patients' life quality once treatment finished, evaluated using the EORTC QLQ-C30 and EORTC QLQ-CR29 questionnaires.

Interventions

DRUGPaclitaxel Hospira 6 mg/ml concentrado para solución para perfusión EFG
DRUGCisplatino Pharmacia 1 mg/ml concentrado para solución para perfusión EFG

Sponsors

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia, Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The safety variable of the study will be postoperative Morbidity and Mortality. Morbidity will be defined based on the NCI‐CTCAE v4 scale classification., The variables related to the treatment effectiveness will be disease free and overall survival.—

Secondary

MeasureTime frame
The secondary variable will be the patients' life quality once treatment finished, evaluated using the EORTC QLQ-C30 and EORTC QLQ-CR29 questionnaires.—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026